CDG and immune response: From bedside to bench and back

Journal of Inherited Metabolic Disease

Volumn 43, Issue 1, 2020, Pages 90-124

  Pascoal, Carlota ^a,b,c   Francisco, Rita ^a,b,c   Ferro, Tiago ^b,c   dos Reis Ferreira, Vanessa ^a,b   Jaeken, Jaak ^b,d   Videira, Paula A ^a,b,c  

^a Portuguese Association for Congenital Disorders of Glycosylation (CDG)   (Portugal)

^b Professional and Patient Association International Network (PPAIN)   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

autoimmune disease; congenital disorders of glycosylation; immune system; immunodeficiency; infection; inflammation

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALG1 PROTEIN; ALG14 PROTEIN; ATP6AP1 PROTEIN; ATP6AP2 PROTEIN; C1GALT1C1 PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; COG6 PROTEIN; DOLK PROTEIN; EXTL3 PROTEIN; FUCOSYLTRANSFERASE; FUT8 PROTEIN; G6PC3 PROTEIN; GALNT3 PROTEIN; GLUCOSE 6 PHOSPHATE; GLYCOSYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGN1 PROTEIN; MAN1B1 PROTEIN; MGAT2 PROTEIN; MOGS PROTEIN; PHOSPHOGLUCOMUTASE; PHOSPHOGLUCOMUTASE 3; PMM2 PROTEIN; SLC37A4 PROTEIN; SLC39A8 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VPS13B PROTEIN;

ALG1 GENE; ALG14 GENE; ATP6AP1 GENE; ATP6AP2 GENE; AUTOIMMUNE DISEASE; C1GALT1C1 GENE; COG6 GENE; CONGENITAL DISORDER OF GLYCOSYLATION; DOLK GENE; EXTL3 GENE; FUT8 GENE; G6PC3 GENE; GALNT3 GENE; GENE; GENE MUTATION; GENETIC IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; INTRACELLULAR SIGNALING; JAGN1 GENE; MAN1B1 GENE; MGAT2 GENE; MOGS GENE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PGM3 GENE; PMM2 GENE; PROTEIN GLYCOSYLATION; QUALITY OF LIFE; REVIEW; SLC35C1 GENE; SLC37A4 GENE; SLC39A8 GENE; VPS13B GENE; GENETICS; IMMUNOLOGY; PHENOTYPE;

CONGENITAL DISORDERS OF GLYCOSYLATION; HUMANS; INFLAMMATION; PHENOTYPE;

EID: 85068160845     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1002/jimd.12126     Document Type: Review

References (273)

1. An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr Opin Chem Biol. 2009;13:421-426.
2. Jensen PH, Karlsson NG, Kolarich D, Packer NH. Structural analysis of N- and O-glycans released from glycoproteins. Nat Protoc. 2012;7:1299-1310.
3. Mitra N, Sharon N, Surolia A. Role of N-linked glycan in the unfolding pathway of Erythrina corallodendron lectin. Biochemistry. 2003;42(42):12208-12216. https://doi.org/10.1021/BI035169E.
4. Piller F, Piller V, Fox RI, Fukuda M. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis. J Biol Chem. 1988;263:15146-15150.
5. Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol. 2005;15:364-370.
6. Imai N et al. Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem. 1990;194:457-462.
7. Varki A, Sharon N. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
8. Gabius HJ. The sugar code: why glycans are so important. Biosystems. 2018;164:102-111.
9. Varki A. Biological roles of glycans. Glycobiology. 2017;27:3-49.
10. Boscher C, Dennis JW, Nabi IR. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol. 2011;23:383-392.
11. Videira PAQ, Castro-Caldas M. Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson's disease. Front Neurosci. 2018;12(381).
12. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. Nat Med. 2011;17:552-553.
13. Scott DW, Tolbert CE, Graham DM, Wittchen E, Bear JE, Burridge K. N-glycosylation controls the function of junctional adhesion molecule-A. Mol Biol Cell. 2015;26:3205-3214.
14. Lyons JJ, Rosenzweig SD, Milner JD, Rosenzweig SD. Glycans instructing immunity: the emerging role of altered glycosylation in clinical immunology. Front Pediatr. 2015;3(54).
15. Ferreira CR, Altassan R, Marques-da-Silva D, Francisco R, Jaeken J, Morava E. Recognizable phenotypes in CDG. J Inherit Metab Dis. 2018;41:541-553.
16. Vajaria BN, Patel PS. Glycosylation: a hallmark of cancer? Glycoconj J. 2017;34:147-156.
17. Grigorian A, Mkhikian H, Li CF, Newton BL, Zhou RW, Demetriou M. Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation. Semin Immunopathol. 2012;34:415-424.
18. Francisco R, Marques-da-Silva D, Brasil S, et al. The challenge of CDG diagnosis. Mol Genet Metab. 2019;126:1-5.
19. Marquardt T, et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999;94(12):3976-3985.
20. Monticelli M, Ferro T, Jaeken J, dos Reis Ferreira V, Videira PA. Immunological aspects of congenital disorders of glycosylation (CDG): a review. J Inherit Metab Dis. 2016;39:765-780.
21. Varki A et al. Essentials of Glycobiology. Essentials of Glycobiology. New York, USA: Cold Spring Harbor Laboratory Press; 2009.
22. Pereira MS, Alves I, Vicente M, et al. Glycans as key checkpoints of T cell activity and function. Front Immunol. 2018;9:2754.
23. Chaplin DD. The human immune response. Clinical Immunology. Amsterdam, The Netherlands: Content Repository Only! 2019. https://doi.org/10.1016/B978-0-7020-6896-6.00001-6.
24. Bartsch YC, Rahmöller J, Mertes MMM, et al. Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of lupus nephritis and rheumatoid arthritis. Front Immunol. 2018;9(1183).
25. de Haan N et al. Differences in IgG Fc glycosylation are associated with outcome of pediatric meningococcal sepsis. MBio. 2018;9:1-13.
26. Shirouzono T, Chirifu M, Nakamura C, Yamagata Y, Ikemizu S. Preparation, crystallization and preliminary X-ray diffraction studies of the glycosylated form of human interleukin-23. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012;68:432-435.
27. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the Mannan-binding lectin pathway. J Immunol. 2001;167:2861-2868.
28. Hinshelwood J, Spencer DIR, Edwards YJK, Perkins SJ. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B. J Mol Biol. 1999;294:587-599.
29. Siddiqui S, Schwarz F, Springer S, et al. Studies on the detection, expression, glycosylation, dimerization, and ligand binding properties of mouse Siglec-E. J Biol Chem. 2017;292:1029-1037.
30. Hauser MA, Kindinger I, Laufer JM, et al. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses. J Leukoc Biol. 2016;99:993-1007.
31. Ghoshal P, Rajendran M, Odo N, Ikuta T. Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells. PLoS One. 2014;9:e99363.
32. Scott DW, Dunn TS, Ballestas ME, Litovsky SH, Patel RP. Identification of a high-mannose ICAM-1 glycoform: effects of ICAM-1 hypoglycosylation on monocyte adhesion and outside in signaling. Am. J. Physiol. Physiol. 2013;305:C228-C237.
33. Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW. Intrapersonal and Populational heterogeneity of the chemokine RANTES. Clin Chem. 2010;56:1432-1441.
34. Kuehn MJ, Heuser J, Normark S, Hultgren SJ. P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature. 1992;356:252-255.
35. Ricciuto J, Heimer SR, Gilmore MS, Argüeso P. Cell surface O-glycans limit Staphylococcus aureus adherence to corneal epithelial cells. Infect Immun. 2008;76:5215-5220.
36. Takamatsu S et al. Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy. Glycobiology. 2016;26:1180-1189.
37. Krishnan S, Prasadarao NV. Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein a. Microbes Infect. 2014;16:540-552.
38. Laughlin RS, Musch MW, Hollbrook CJ, Rocha FM, Chang EB, Alverdy JC. The key role of Pseudomonas aeruginosa PA-I lectin on experimental gut-derived sepsis. Ann Surg. 2000;232:133-142.
39. Chemani C, Imberty A, de Bentzmann S, et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun. 2009;77:2065-2075.
40. Samji T. Influenza a: understanding the viral life cycle. Yale J Biol Med. 2009;82:153-159.
41. Geoghegan EM, Pastrana DV, Schowalter RM, et al. Infectious entry and neutralization of pathogenic JC polyomaviruses. Cell Rep. 2017;21:1169-1179.
42. Boltin D, Perets TT, Vilkin A, Niv Y. Mucin function in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:106-111.
43. Corfield AP. The interaction of the gut microbiota with the mucus barrier in health and disease in human. Microorganisms. 2018;6:E78.
44. Gerlach D, Guo Y, de Castro C, et al. Methicillin-resistant Staphylococcus aureus alters cell wall glycosylation to evade immunity. Nature. 2018;563:705-709.
45. Park JH, Hogrebe M, Fobker M, et al. SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy. Genet Med. 2018;20:259-268.
46. Han J, Perez JT, Chen C, et al. Genome-wide CRISPR/Cas9 screen identifies host factors essential for influenza virus replication. Cell Rep. 2018;23:596-607.
47. Chang J, Block TM, Guo JT. Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections. Antivir Ther. 2015;20:257-259.
48. Rudd PM, Wormald MR, Stanfield RL, et al. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. J Mol Biol. 1999;293:351-366.
49. Kuball J, Hauptrock B, Malina V, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N -glycosylation sites in the TCR constant domain. J Exp Med. 2009;206:463-475.
50. Weber ANR, Morse MA, Gay NJ. Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J Biol Chem. 2004;279:34589-34594.
51. Sun J, Duffy KE, Ranjith-Kumar CT, et al. Structural and functional analyses of the human toll-like receptor 3: role of glycosylation. J Biol Chem. 2006;281:11144-11151.
52. da Silva Correia J, Ulevitch RJ. MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem. 2002;277:1845-1854.
53. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5N-glycosylation. Nature. 2001;409:733-739.
54. Lund PJ, Elias JE, Davis MM. Global analysis of O -GlcNAc glycoproteins in activated human T cells. J Immunol. 2016;197:3086-3098.
55. Te Riet J, Joosten B, Reinieren-Beeren I, Figdor CG, Cambi A. N-glycan mediated adhesion strengthening during pathogen-receptor binding revealed by cell-cell force spectroscopy. Sci Rep. 2017;7(6713).
56. Silva M, Silva Z, Marques G, et al. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Oncotarget. 2016;7:41053–41066.
57. Ferro T et al. MHC class I stability is modulated by cell surface sialylaion in human dendritic cells. European Journal of Immunology; 2018:46-47.
58. Ryan SO, Bonomo JA, Zhao F, Cobb BA. MHCII glycosylation modulates Bacteroides fragilis carbohydrate antigen presentation. J Exp Med. 2011;208:1041-1053.
59. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (80-.). 2006;313:670-673.
60. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (80-.). 2008;320:373-376.
61. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo. Curr Opin Organ Transplant. 2011;16:7-14.
62. Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123:2183-2192.
63. Varki A. Selectin ligands. Proc Natl Acad Sci USA. 1994;91:7390-7397.
64. Kawashima H, Fukuda M. Sulfated glycans control lymphocyte homing. Ann N Y Acad Sci. 2012;1253:112-121.
65. Silva M, Fung RKF, Donnelly CB, Videira PA, Sackstein R. Cell-specific variation in E-selectin ligand expression among human peripheral blood mononuclear cells: implications for immunosurveillance and pathobiology. J Immunol. 2017;198:3576-3587.
66. Silva M, Videira PA, Sackstein R. E-selectin ligands in the human mononuclear phagocyte system: implications for infection, inflammation, and immunotherapy. Front Immunol. 2018;8(1878).
67. Videira PA, Silva M, Martin KC, Sackstein R. Ligation of the CD44 Glycoform HCELL on culture-expanded human monocyte-derived dendritic cells programs Transendothelial migration. J Immunol. 2018;201:1030-1043.
68. Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrín D, Stehle T. Structural basis for sialic acid–mediated self-recognition by complement factor H. Nat Chem Biol. 2015;11:77-82.
69. Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proc Natl Acad Sci USA. 2016;113:3329-3334.
70. Crespo HJ, Guadalupe Cabral M, Teixeira AV, Lau JTY, Trindade H, Videira PA. Effect of sialic acid loss on dendritic cell maturation. Immunology. 2009;128:e621-e631.
71. Cabral MG, Silva Z, Ligeiro D, et al. The phagocytic capacity and immunological potency of human dendritic cells is improved by α2,6-sialic acid deficiency. Immunology. 2013;138:235-245.
72. Dimitrov B, Himmelreich N, Hipgrave Ederveen AL, et al. Cutis laxa, exocrine pancreatic insufficiency and altered cellular metabolomics as additional symptoms in a new patient with ATP6AP1-CDG. Mol Genet Metab. 2018;123:364-374.
73. Jansen EJR, Timal S, Ryan M, et al. ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive impairment and abnormal protein glycosylation. Nat Commun. 2016;7:11600.
74. Volpi S, Yamazaki Y, Brauer PM, et al. EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay. J Exp Med. 2017;214:623-637.
75. Oud MM, Tuijnenburg P, Hempel M, et al. Mutations in EXTL3 cause neuro-immuno-skeletal dysplasia syndrome. Am J Hum Genet. 2017;100:281-296.
76. Guo L, Elcioglu NH, Mizumoto S, et al. Identification of biallelic EXTL3 mutations in a novel type of spondylo-epi-metaphyseal dysplasia. J Hum Genet. 2017;62:797-801.
77. Ng BG et al. Biallelic mutations in FUT8 cause a congenital disorder of glycosylation with defective fucosylation. Am J Hum Genet. 2018;102:188-195.
78. Boztug K, Appaswamy G, Ashikov A, et al. A novel syndrome with congenital neutropenia caused by mutations in G6PC3. N Engl J Med. 2009;360:32-43.
79. Arostegui JI, de Toledo JS, Pascal M, Garcia C, Yague J, Diaz de Heredia C. A novel G6PC3 homozygous 1-bp deletion as a cause of severe congenital neutropenia. Blood. 2009;114:1718-1719.
80. Xia J, Bolyard AA, Rodger E, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009;147:535-542.
81. Germeshausen M, Zeidler C, Stuhrmann M, Lanciotti M, Ballmaier M, Welte K. Digenic mutations in severe congenital neutropenia. Haematologica. 2010;95:1207-1210.
82. Eghbali A, Eshghi P, Malek F, Rezaei N. Cardiac and renal malformations in a patient with sepsis and severe congenital neutropenia. Iran J Pediatr. 2010;20:225-228.
83. McDermott DH, de Ravin SS, Jun HS, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010;116:2793-2802.
84. Banka S, Newman WG, Özgül RK, Dursun A. Mutations in the G6PC3 gene cause Dursun syndrome. Am J Med Genet Part A. 2010;152 A:2609-2611.
85. Banka S, Chervinsky E, Newman WG, et al. Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3. Eur J Hum Genet. 2011;19:18-22.
86. Gatti S, Boztug K, Pedini A, et al. A case of syndromic neutropenia and mutation in G6PC3. J Pediatr Hematol Oncol. 2011;33:138-140.
87. Hayee B, Antonopoulos A, Murphy EJ, et al. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. Glycobiology. 2011;21:914-924.
88. Cullinane AR, Vilboux T, O'Brien K, et al. Homozygosity mapping and whole-exome sequencing to detect SLC45A2 and G6PC3 mutations in a single patient with oculocutaneous albinism and neutropenia. J Invest Dermatol. 2011;131:2017-2025.
89. Alizadeh Z et al. Two cases of syndromic neutropenia with a report of novel mutation in G6PC3. Iran J Allergy, Asthma Immunol. 2011;10:227-230.
90. Boztug K, Rosenberg PS, Dorda M, et al. Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr. 2012;160:679-683.e2.
91. Smith BN, Evans C, Ali A, et al. Phenotypic heterogeneity and evidence of a founder effect associated with G6PC3 mutations in patients with severe congenital neutropenia. Br J Haematol. 2012;158:146-149.
92. Fernandez BA et al. Adult siblings with homozygous G6PC3 mutations expand our understanding of the severe congenital neutropenia type 4 (SCN4) phenotype. BMC Med Genet. 2012;13(111).
93. Aytekin C, Germeshausen M, Tuygun N, Dogu F, Ikinciogullari A. A novel G6PC3 gene mutation in a patient with severe congenital neutropenia. J Pediatr Hematol Oncol. 2013;35:e81-e83.
94. Bégin P, Patey N, Mueller P, et al. Inflammatory bowel disease and T cell lymphopenia in G6PC3 deficiency. J Clin Immunol. 2013;33:520-525.
95. Banka S, Wynn R, Byers H, Arkwright PD, Newman WG. G6PC3 mutations cause non-syndromic severe congenital neutropenia. Mol Genet Metab. 2013;108:138-141.
96. Estévez OA, Ortega C, Tejero Á, et al. A novel phenotype variant of severe congenital neutropenia caused by G6PC3 deficiency. Pediatr Blood Cancer. 2013;60:E29-E31.
97. Alizadeh Z et al. Different pattern of gene mutations in Iranian patients with severe congenital. Iran J Allergy Asthma Immunol. 2013;12:86-92.
98. Matthews MAB, Adler BH, Arnold MA, Kumar S, Carvalho R, Besner GE. Diffuse intestinal ganglioneuromatosis in a child. J Pediatr Surg. 2013;48:1129-1133.
99. Alangari AA, Alsultan A, Osman ME, Anazi S, Alkuraya FS. A novel homozygous mutation in G6PC3 presenting as cyclic neutropenia and severe congenital neutropenia in the same family. J Clin Immunol. 2013;33:1403-1406.
100. Kaya Z, Eğritaş Ö, Albayrak M, et al. Resolution of inflammatory colitis with pegfilgrastim treatment in a case of severe congenital neutropenia due to glucose 6 phosphatase catalytic subunit-3 deficiency. J Pediatr Hematol Oncol. 2014;36:316-318.
101. Tavil B, Cetin M, Gumruk F. Sea-blue histiocytes in the bone marrow of a boy with severe congenital neutropenia associated with G6PC3 mutation. Br J Haematol. 2014;165:426.
102. Özgül RK, Yücel-YIlmaz D, Dursun A. Dursun syndrome due to G6PC3 gene defect has a fluctuating pattern in all blood cell lines. J Clin Immunol. 2014;34:265-266.
103. Yeshayahu Y, Asaf R, Dubnov-Raz G, et al. Testicular failure in a patient with G6PC3 deficiency. Pediatr Res. 2014;76:197-201.
104. Notarangelo LD, Savoldi G, Cavagnini S, et al. Severe congenital neutropenia due to G6PC3 deficiency: early and delayed phenotype in two patients with two novel mutations. Ital J Pediatr. 2014;40(80):80.
105. Desplantes C et al. Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry. Orphanet J Rare Dis. 2014;9:1-15.
106. Kiykim A, Baris S, Karakoc-Aydiner E, et al. G6PC3 deficiency: primary immune deficiency beyond just neutropenia. J Pediatr Hematol Oncol. 2015;37:616-622.
107. Arikoglu T, Kuyucu N, Germeshausen M, Kuyucu S. A novel G6PC3 gene mutation in severe congenital neutropenia: pancytopenia and variable bone marrow phenotype can also be part of this syndrome. Eur J Haematol. 2015;94:79-82.
108. Lebel A, Yacobovich J, Krasnov T, et al. Genetic analysis and clinical picture of severe congenital neutropenia in Israel. Pediatr Blood Cancer. 2015;62:103-108.
109. Cihan MK et al. A severe congenital neutropenia type 4 case (G6PC3 mutation) presented with large platelets in the peripheral smear. J Pediatr Hematol Oncol. 2016;38:324-328.
110. Glasser CL, Picoraro JA, Jain P, et al. Phenotypic heterogeneity of neutropenia and gastrointestinal illness associated with G6PC3 founder mutation. J Pediatr Hematol Oncol. 2016;38:e243-e247.
111. Mistry A, Scambler T, Parry D, et al. Glucose-6-phosphatase catalytic subunit 3 (G6PC3) deficiency associated with autoinflammatory complications. Front Immunol. 2017;8(1485).
112. Olcay L et al. Both granulocytic and non-granulocytic blood cells are affected in patients with severe congenital neutropenia and their non-neutropenic family members: An evaluation of morphology, function, and cell death. Turkish J Hematol. 2018;35:229-259.
113. Gong R-L, Wu J, Chen T-X. Clinical, laboratory, and molecular characteristics and remission status in children with severe congenital and non-congenital neutropenia. Front Pediatr. 2018;6(305).
114. Olcay L, Yetgin S, Erdemli E, et al. Congenital dysgranulopoietic neutropenia. Pediatr Blood Cancer. 2008;50:115-119.
115. Boztug K, Järvinen PM, Salzer E, et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat Genet. 2014;46:1021-1027.
116. Baris S, Karakoc–Aydiner E, Ozen A, et al. JAGN1 deficient severe congenital neutropenia: two cases from the same family. J Clin Immunol. 2015;35:339-343.
117. Khandagale A, Lazzaretto B, Carlsson G, et al. JAGN1 is required for fungal killing in neutrophil extracellular traps: implications for severe congenital neutropenia. J Leukoc Biol. 2018;104:1199-1213.
118. Bernth-Jensen JM, Holm M, Christiansen M. Neonatal-onset T-B-NK+severe combined immunodeficiency and neutropenia caused by mutated phosphoglucomutase 3. J Allergy Clin Immunol. 2016;137:321-324.
119. Ben-Khemis L, Mekki N, Ben-Mustapha I, et al. A founder mutation underlies a severe form of phosphoglutamase 3 (PGM3) deficiency in Tunisian patients. Mol Immunol. 2017;90:57-63.
120. Pacheco-Cuéllar G, Gauthier J, Désilets V, et al. A novel PGM3 mutation is associated with a severe phenotype of bone marrow failure, severe combined immunodeficiency, skeletal dysplasia, and congenital malformations. J Bone Miner Res. 2017;32:1853-1859.
121. Lundin KE, Wang Q, Hamasy A, et al. Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report. BMC Pediatr. 2018;18(285):285.
122. Gerin I, Veiga-Da-Cunha M, Achouri Y, Collet JF, Van Schaftingen E. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. FEBS Lett. 1997;419:235-238.
123. Veiga-da-Cunha M, Gerin I, Chen YT, et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. Am J Hum Genet. 1998;63:976-983.
124. Adachi M, Shinkai M, Ohhama Y, et al. Improved neutrophil function in a glycogen storage disease type 1b patient after liver transplantation. Eur J Pediatr. 2004;163:202-206.
125. Janecke AR, Lindner M, Erdel M, et al. Mutation analysis in glycogen storage disease type 1 non-a. Hum Genet. 2000;107:285-289.
126. Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr. 2005;164:501-508.
127. Choi R, Park HD, Ko JM, et al. Novel SLC37A4 mutations in Korean patients with glycogen storage disease Ib. Ann Lab Med. 2017;37:261-266.
128. Melis D, Pivonello R, Cozzolino M, et al. Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1b. Horm Res Paediatr. 2014;81:55-62.
129. Galli L, Orrico A, Marcolongo P, et al. Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage diseases type 1b and 1c. FEBS Lett. 1999;459:255-258.
130. Hou DC, Kure S, Suzuki Y, et al. Glycogen storage disease type Ib: structural and mutational analysis of the microsomal glucose-6-phosphate transporter gene. Am J Med Genet. 1999;86:253-257.
131. Lam C-W, Chan KY, Tong SF, Chan BY, Chan YT, Chan YW. A novel missense mutation (P191L) in the glucose-6-phosphate translocase gene identified in a Chinese family with glycogen storage disease 1b. Hum Mutat. 2000;16:94-94.
132. Trioche P, Petit F, Francoual J, et al. Allelic heterogeneity of glycogen storage disease type Ib in French patients: a study of 11 cases. J Inherit Metab Dis. 2004;27:621-623.
133. Miltenberger-Miltenyi G, Szonyi L, Balogh L, Utermann G, Janecke AR. Mutation spectrum of type I glycogen storage disease in Hungary. J Inherit Metab Dis. 2005;28:939-944.
134. Kovacevic A, Ehrlich R, Mayatepek E, Wendel U, Schwahn B. Glycogen storage disease type Ib without hypoglycemia. Mol Genet Metab. 2007;90:349-350.
135. Chopra M, Jackson R, Durkie M, Beauchamp NJ, Kirk EP. Glycogen storage disease type 1b: mild phenotype associated with a novel splice site mutation. Mol Genet Metab. 2009;97:315.
136. Zappu A, Lilliu F, Podda RA, Loudianos G. Molecular analysis of glycogen storage disease type Ib in Sardinian population: evidence for a founder effect. Genet Test Mol Biomarkers. 2010;14:399-403.
137. Kure S, Suzuki Y, Matsubara Y, et al. Molecular analysis of glycogen storage disease type Ib: identification of a prevalent mutation among Japanese patients and assignment of a putative glucose-6-phosphate translocase gene to chromosome 11. Biochem Biophys Res Commun. 1998;248:426-431.
138. Kojima K, Kure S, Kamada F, et al. Genetic testing of glycogen storage disease type Ib in Japan: five novel G6PT1 mutations and a rapid detection method for a prevalent mutation W118R. Mol Genet Metab. 2004;81:343-346.
139. Mameesh M, Ganesh A, Harikrishna B, et al. Co-inheritance of the membrane frizzled-related protein ocular phenotype and glycogen storage disease type Ib. Ophthalmic Genet. 2017;38:544-548.
140. Prasad R, Estrella J, Christodoulou J, McKellar G, Tchan MC. A third case of glycogen storage disease IB and Giant cell tumour of the mandible: a disease association or iatrogenic complication of therapy. JIMD Rep. 2017;42:5-8.
141. Marcolongo P, Barone V, Priori G, et al. Structure and mutation analysis of the glycogen storage disease type 1b gene. FEBS Lett. 1998;436:247-250.
142. Veiga-da-Cunha M, Gerin I, Chen YT, et al. The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet. 1999;7:717-723.
143. Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European study on glycogen storage disease type I. J Pediatr. 2000;137:187-191.
144. Melis D et al. Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? J Inherit Metab Dis. 2008;31:S227-S231.
145. Hsiao HJ, Chang HH, Hwu WL, Lam CW, Lee NC, Chien YH. Glycogen storage disease type Ib: the first case in Taiwan. Pediatr Neonatol. 2009;50:125-128.
146. Melis D, Della Casa R, Parini R, et al. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b. Eur J Pediatr. 2009;168:1069-1074.
147. Dissanayake VH, Jayasinghe JD, Thilakaratne V, Jayasekara RW. A novel mutation in SLC37A4 gene in a Sri Lankan boy with glycogen storage disease type Ib associated with very early onset neutropenia. J Mol Genet Med. 2011;5:262-263.
148. Wang J, Cui H, Lee NC, et al. Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin. Genet Med. 2013;15:106-114.
149. Melis D, Casa RD, Balivo F, et al. Involvement of endocrine system in a patient affected by glycogen storage disease 1b: speculation on the role of autoimmunity. Ital J Pediatr. 2014;40(30).
150. Oguz MM et al. Glycogen storage disease type 1B: An early onset severe phenotype associated with a novel mutation (IVS4) in the glucose 6-phosphate translocase (SLC37A4) gene in a Turkish patient. Genet Couns. 2014;25:589-594.
151. Lee KJ, Choi SJ, Kim WS, Park SS, Moon JS, Ko JS. Esophageal stricture secondary to candidiasis in a child with glycogen storage disease 1b. Pediatr Gastroenterol Hepatol Nutr. 2016;19:71-75.
152. Letkemann R, Wittkowski H, Antonopoulos A, et al. Partial correction of neutrophil dysfunction by oral galactose therapy in glycogen storage disease type Ib. Int Immunopharmacol. 2017;44:216-225.
153. Skakic A, Djordjevic M, Sarajlija A, et al. Genetic characterization of GSD I in Serbian population revealed unexpectedly high incidence of GSD Ib and 3 novel SLC37A4 variants. Clin Genet. 2018;93:350-355.
154. Landi A, Vermeire J, Iannucci V, et al. Genome-wide shRNA screening identifies host factors involved in early endocytic events for HIV-1-induced CD4 down-regulation. Retrovirology. 2014;11:118.
155. Perreira JM, Aker AM, Savidis G, et al. RNASEK is a V-ATPase-associated factor required for endocytosis and the replication of rhinovirus, influenza a virus, and dengue virus. Cell Rep. 2015;12:850-863.
156. Wang X, Inoue S, Gu J, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA. 2005;102:15791-15796.
157. Kamio K, Yoshida T, Gao C, et al. α1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD). Biochem Biophys Res Commun. 2012;424:112-117.
158. Li W, Yu R, Ma B, et al. Core Fucosylation of IgG B cell receptor is required for antigen recognition and antibody production. J Immunol. 2015;194:2596-2606.
159. Liang W, Mao S, Sun S, et al. Core fucosylation of the T cell receptor is required for T cell activation. Front Immunol. 2018;9:78.
160. Li W, Ishihara K, Yokota T, et al. Reduced α4β1 integrin/VCAM-1 interactions lead to impaired pre-B cell repopulation in alpha 1,6-fucosyltransferase deficient mice. Glycobiology. 2008;18:114-124.
161. Li W, Liu Q, Pang Y, et al. Core fucosylation of μ heavy chains regulates assembly and intracellular signaling of precursor B cell receptors. J Biol Chem. 2012;287:2500-2508.
162. Iijima J, Kobayashi S, Kitazume S, et al. Core fucose is critical for CD14-dependent toll-like receptor 4 signaling. Glycobiology. 2017;27:1006-1015.
163. Mazer BD et al. Genome-wide association study on immunoglobulin G glycosylation patterns. Front Immunol. 2018;9:1-14.
164. Fujii H, Shinzaki S, Iijima H, et al. Core Fucosylation on T cells, required for activation of T-cell receptor signaling and induction of colitis in mice, is increased in patients with inflammatory bowel disease. Gastroenterology. 2016;150:1620-1632.
165. Wirnsberger G, Zwolanek F, Stadlmann J, et al. Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense. Nat Genet. 2014;46:1028-1033.
166. Lundin KE, Hamasy A, Backe PH, et al. Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene. Clin Immunol. 2015;161:366-372.
167. Wu G, Hitchen PG, Panico M, et al. Glycoproteomic studies of IgE from a novel hyper IgE syndrome linked to PGM3 mutation. Glycoconj J. 2016;33:447-456.
168. Plomp R, Hensbergen PJ, Rombouts Y, et al. Site-specific N-glycosylation analysis of human immunoglobulin e. J Proteome Res. 2014;13:536-546.
169. Sassi A, Lazaroski S, Wu G, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol. 2014;133:1410-1419.
170. Golks A, Tran TTT, Goetschy JF, Guerini D. Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes activation. EMBO J. 2007;26:4368-4379.
171. Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the transcriptional function of the NF- B protein c-Rel by O-GlcNAc glycosylation. Sci Signal. 2013;6:ra75.
172. Marquardt T et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 2012;94:3976-3985.
173. Lühn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001;28:69-72.
174. Kim SYSY, Jun HS, Mead PA, Mansfield BC, Chou JY. Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood. 2008;111:5704-5711.
175. Leuzzi R, Bánhegyi G, Kardon T, et al. Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b. Blood. 2003;101:2381-2387.
176. Chen LY, Shieh JJ, Lin B, et al. Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet. 2003;12:2547-2558.
177. Jun HS, Weinstein DA, Lee YM, Mansfield BC, Chou JY. Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. Blood. 2014;123:2843-2853.
178. Ng BG, et al. ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients. Hum Mutat. 2016;7:653-660.
179. Marques-da-Silva D, dos Reis Ferreira V, Monticelli M, et al. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J Inherit Metab Dis. 2017;40:195-207.
180. Harshman LA, Ng BG, Freeze HH, et al. Congenital nephrotic syndrome in an infant with ALG1 -congenital disorder of glycosylation. Pediatr Int. 2016;58:785-788.
181. Fiumara A, Barone R, Del Campo G, Striano P, Jaeken J. Electroclinical features of early-onset epileptic encephalopathies in congenital disorders of glycosylation (CDGs). JIMD Rep. 2015;27:93-99.
182. Cossins J, Belaya K, Hicks D, et al. Congenital myasthenic syndromes due to mutations in ALG2 and ALG14. Brain. 2013;136:944-956.
183. Rujano MA, Cannata Serio M, Panasyuk G, et al. Mutations in the X-linked ATP6AP2 cause a glycosylation disorder with autophagic defects. J Exp Med. 2017;214:3707-3729.
184. Wendling O, Champy MF, Jaubert S, et al. Atp6ap2 ablation in adult mice impairs viability through multiple organ deficiencies. Sci Rep. 2017;7(9618).
185. Narumi K, Hirose T, Sato E, et al. A functional (pro)renin receptor is expressed in human lymphocytes and monocytes. Am J Physiol Physiol. 2015;308:F487-F499.
186. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113.
187. Miyazaki N et al. Expression of prorenin receptor in renal biopsies from patients with IgA nephropathy. Int J Clin Exp Pathol. 2014;7:7485-7496.
188. Mizuguchi Y, Morimoto S, Kimura S, et al. Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease. PLoS One. 2018;13:e0195464.
189. Fu J, Wei B, Wen T, et al. Loss of intestinal core 1–derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 2011;121:1657-1666.
190. Karamatic CV et al. New mutations in C1GALT1C1 in individuals with Tn positive phenotype. Science (80-.). 2008;142:657-667.
191. Ju T, Cummings RDP g. Chaperone mutation in Tn syndrome. Nature. 2005;437:1252.
192. Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25:3890-3897.
193. Sun Q, Zhang J, Zhou N, Liu X, Shen Y. DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy. PLoS One. 2015;10:e0112305.
194. Xiao J, Wang M, Xiong D, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and Cosmc. Mol Med Rep. 2017;15:969-974.
195. He L, Peng Y, Liu H, et al. Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol. 2013;38:321-332.
196. Hu S, Bao H, Xu X, et al. Increased MIR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy. FEBS Lett. 2015;589:4019-4025.
197. Yang L, Zhang XY, Peng W, Wei M, Qin W. MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy. Int Urol Nephrol. 2017;49:353-361.
198. Lin JR, Wen J, Zhang H, et al. Interleukin-17 promotes the production of underglycosylated IgA1 in DAKIKI cells. Ren Fail. 2018;40:60-67.
199. Van Vliet SJ et al. Human T cell activation results in extracellular signal-regulated kinase (ERK)-calcineurin-dependent exposure of Tn antigen on the cell surface and binding of the macrophage galactose-type lectin (MGL). J Biol Chem. 2013;288:27519-27532.
200. Xie LS, Qin W, Fan JM, Huang J, Xie XS. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clin Investig Med. 2010;33:e5-e13.
201. Ji L, Chen XL, Zhong X, et al. Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy. BMC Complement Altern Med. 2014;14(195).
202. Yang M, Li FG, Xie XS, Wang SQ, Fan JM. CagA, a major virulence factor of helicobacter pylori, promotes the production and underglycosylation of IgA1 in DAKIKI cells. Biochem Biophys Res Commun. 2014;444:276-281.
203. Li G et al. Compound heterozygous variants of the COG6 gene in a Chinese patient with deficiency of subunit 6 of the conserved oligomeric Golgi complex (COG6-CDG). Eur J Med Genet. 2018;62:44-46.
204. Althonaian N, Alsultan A, Morava E, Alfadhel M. Secondary Hemophagocytic syndrome associated with COG6 gene defect: report and review. JIMD Rep. 2018;42:105-111.
205. Cavalli M, Pan G, Nord H, et al. Allele-specific transcription factor binding to common and rare variants associated with disease and gene expression. Hum Genet. 2016;135:485-497.
206. Márquez A, Vidal-Bralo L, Rodríguez-Rodríguez L, et al. A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2017;76:286-294.
207. Rush ET, Baker CV, Rizzo WB. Dolichol kinase deficiency (DOLK-CDG): two new cases and expansion of phenotype. Am J Med Genet A. 2017;173:2428-2434.
208. Ramnitz MS, Gourh P, Goldbach-Mansky R, et al. Phenotypic and genotypic characterization and treatment of a cohort with familial Tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J Bone Miner Res. 2016;31:1845-1854.
209. Jaeken J, Schachter H, Carchon H, de Cock P, Coddeville B, Spik G. Carbohydrate deficient glycoprotein syndrome type II: a deficiency in golgi localised n-acetyl-glucosaminyltransferase II. Arch Dis Child. 1994;71:123-127.
210. Alsubhi S et al. Congenital disorders of glycosylation: The Saudi experience. Am J Med Genet A. 2017;173:2614-2621.
211. Jones MB, Ryan SO, Johnson JL, Cobb BA. Dendritic cell-specific Mgat2 knockout mice show antigen presentation defects but reveal an unexpected CD11c expression pattern. Glycobiology. 2016;26:1007-1013.
212. Ryan SO, Leal SM, Abbott DW, Pearlman E, Cobb BA. Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses. Glycobiology. 2014;24:262-271.
213. Ryan SO, Abbott DW, Cobb BA. Myeloid glycosylation defects Lead to a spontaneous common variable immunodeficiency-like condition with associated hemolytic Anemia and Antilymphocyte autoimmunity. J Immunol. 2014;192:5561-5570.
214. Izquierdo-Serra M, Martínez-Monseny A, López L, et al. Stroke-like episodes and cerebellar syndrome in phosphomannomutase deficiency (PMM2-CDG): evidence for hypoglycosylation-driven channelopathy. Int J Mol Sci. 2018;19:619.
215. Wu J, Hong L, Chen TX. Clinical manifestation of hyper IgE syndrome including otitis media. Curr Allergy Asthma Rep. 2018;18(51):51.
216. Asteggiano CG, Papazoglu M, Bistué Millón MB, et al. Ten years of screening for congenital disorders of glycosylation in Argentina: case studies and pitfalls. Pediatr Res. 2018;84:837-841.
217. Riley LG, Cowley MJ, Gayevskiy V, et al. A SLC39A8 variant causes manganese deficiency, and glycosylation and mitochondrial disorders. J Inherit Metab Dis. 2017;40:261-269.
218. Park JH et al. SLC39A8 deficiency: a disorder of manganese transport and glycosylation. Am J Hum Genet. 2015;97:894-903.
219. Boycott KM, Beaulieu CL, Kernohan KD, et al. Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am J Hum Genet. 2015;97:886-893.
220. Li D, Achkar JP, Haritunians T, et al. A pleiotropic missense variant in SLC39A8 is associated with Crohn's disease and human gut microbiome composition. Gastroenterology. 2016;151:724-732.
221. Zhang Q, Boisson B, Béziat V, Puel A, Casanova J-LL. Human hyper-IgE syndrome: singular or plural? Mamm Genome. 2018;29:603-617.
222. Gálvez-Peralta M, Wang Z, Bao S, Knoell DL, Nebert DW. Tissue-specific induction of mouse ZIP8 and ZIP14 divalent cation/bicarbonate symporters by, and cytokine response to, inflammatory signals. Int J Toxicol. 2014;33:246-258.
223. Gálvez-Peralta M, He L, Jorge-Nebert LF, et al. Zip8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero. PLoS One. 2012;7:e36055.
224. Chen J et al. In utero gene expression in the Slc39a8(neo/neo) knockdown mouse. Sci Rep. 2018;8:1-14.
225. Duplomb L et al. Cohen syndrome is associated with major glycosylation defects. Hum Mol Genet. 2013;23:2391-2399.
226. Balikova I, Lehesjoki AE, de Ravel TJL, et al. Deletions in the VPS13B (COH1) gene as a cause of Cohen syndrome. Hum Mutat. 2009;30(845–854):E845-E854.
227. Khan A, Chandler K, Pimenides D, Black GCM, Manson FDC. Corneal ectasia associated with Cohen syndrome: a role for COH1 in corneal development and maintenance? Br J Ophthalmol. 2006;90:390-391.
228. Kolehmainen J, Black GCM, Saarinen A, et al. Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport. Am J Hum Genet. 2003;72:1359-1369.
229. Kolehmainen J, Wilkinson R, Lehesjoki AE, et al. Delineation of Cohen syndrome following a large-scale genotype-phenotype screen. Am J Hum Genet. 2004;75:122-127.
230. Kondo I, Shimizu A, Asakawa S, et al. COH1 analysis and linkage study in two Japanese families with Cohen syndrome. Clin Genet. 2005;67:270-272.
231. Mochida GH et al. Broader geographical spectrum of Cohen syndrome due to COH1 mutations. J Med Genet. 2004;41:1-4.
232. Parri V, Katzaki E, Uliana V, et al. High frequency of COH1 intragenic deletions and duplications detected by MLPA in patients with Cohen syndrome. Eur J Hum Genet. 2010;18:1133-1140.
233. Prokudin I, Li D, He S, et al. Value of whole exome sequencing for syndromic retinal dystrophy diagnosis in young patients. Clin Experiment Ophthalmol. 2015;43:132-138.
234. Rafiq MA, Leblond CS, Saqib MAN, et al. Novel VPS13B mutations in three large Pakistani Cohen syndrome families suggests a Baloch variant with autistic-like features. BMC Med Genet. 2015;16(41):41.
235. Rejeb I et al. First case report of Cohen syndrome in the Tunisian population caused by VPS13B mutations. BMC Med Genet. 2017;18:1-5.
236. Seifert W et al. Mutational spectrum of COH1 and clinical heterogeneity in Cohen syndrome. J Med Genet. 2006;43:1-6.
237. Bugiani M et al. Cohen syndrome resulting from a novel large intragenic COH1 deletion segregating in an isolated Greek Island population. Am. J. Med. Genet. Part A. 2008;146:2221-2226.
238. Seifert W, Holder-Espinasse M, Kühnisch J, et al. Expanded mutational spectrum in Cohen syndrome, tissue expression, and transcript variants of COH1. Hum Mutat. 2009;30(404–420):E404-E420.
239. Uyhazi KE, Binenbaum G, Carducci N, Zackai EH, Aleman TS. Early photoreceptor outer segment loss and retinoschisis in Cohen syndrome. Ophthalmic Genet. 2018;39:399-404.
240. Yang C, Hou M, Li Y, et al. Gene analysis: a rare gene disease of intellectual deficiency-Cohen syndrome. Int J Dev Neurosci. 2018;68:83-88.
241. Beck KD, Wong RW, Gibson JB, Harper CA. Nonleaking cystoid macular edema in Cohen syndrome. J. AAPOS. 2018;S1091-8531:30501-30509.
242. Gillentine MA, Schaaf CP, Patel A. The importance of phase analysis in multiexon copy number variation detected by aCGH in autosomal recessive disorder loci. Am J Med Genet Part A. 2017;173:2485-2488.
243. Carneiro T, Krepischi A, Souza da Costa S, et al. Utility of trio-based exome sequencing in the elucidation of the genetic basis of isolated syndromic intellectual disability: illustrative cases. Appl Clin Genet. 2018;11:93-98.
244. Dastan J et al. Exome sequencing identifies pathogenic variants of VPS13B in a patient with familial 16p11.2 duplication. BMC Med Genet. 2016;17:1-6.
245. El Chehadeh S et al. Search for the best indicators for the presence of a VPS13B gene mutation and confirmation of diagnostic criteria in a series of 34 patients genotyped for suspected Cohen syndrome. J Med Genet. 2010;47:549-553.
246. El Chehadeh-Djebbar S et al. Changing facial phenotype in Cohen syndrome: towards clues for an earlier diagnosis. Eur J Hum Genet. 2013;21:736-742.
247. Falk MJ, Feiler HS, Neilson DE, et al. Cohen syndrome in the Ohio Amish. Am J Med Genet. 2004;128A:23-28.
248. Gueneau L, Duplomb L, Sarda P, et al. Congenital neutropenia with retinopathy, a new phenotype without intellectual deficiency or obesity secondary to VPS13B mutations. Am. J. Med. Genet. Part A. 2014;164:522-527.
249. Katzaki E, Pescucci C, Uliana V, et al. Clinical and molecular characterization of Italian patients affected by Cohen syndrome. J Hum Genet. 2007;52:1011-1017.
250. Horn D, Krebsová A, Kunze J, Reis A. Homozygosity mapping in a family with microcephaly, mental retardation, and short stature to a Cohen syndrome region on 8q21.3—8q22.1: redefining a clinical entity. Am J Med Genet. 2000;92:285-292.
251. Seifert W, Kühnisch J, Maritzen T, Horn D, Haucke V, Hennies HC. Cohen syndrome-associated protein, COH1, is a novel, giant Golgi matrix protein required for Golgi integrity. J Biol Chem. 2011;286:37665-37675.
252. Brasil S, Pascoal C, Francisco R, et al. CDG therapies: from bench to bedside. Int J Mol Sci. 2018;19:1304.
253. Xie L, Tan C, Fan J, et al. Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy. Int Urol Nephrol. 2013;45:571-579.
254. Willig TN et al. Macrothrombocytopenia with abnormal demarcation membranes in megakaryocytes and neutropenia with a complete lack of sialyl-Lewis-X antigen in leukocytes—a new syndrome? Blood. 2001;97:826-828.
255. Ouedraogo R, Flaudrops C, Ben Amara A, Capo C, Raoult D, Mege JL. Global analysis of circulating immune cells by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. PLoS One. 2010;5:e13691.
256. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466-3473.
257. Kanda Y, Yamada T, Mori K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17:104-118.
258. Ito E, Oka R, Ishii T, et al. Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease. J Proteomics. 2015;127:386-394.
259. Okada M, Chikuma S, Kondo T, et al. Blockage of Core Fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 2017;20:1017-1028.
260. Zhu Z, Chen W, Hao L, et al. Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis. J Clin Periodontol. 2015;42:599-608.
261. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65-79.
262. Nakamura S, Horie M, Daidoji T, et al. Influenza a virus-induced expression of a GalNAc transferase, GALNT3, via MicroRNAs is required for enhanced viral replication. J Virol. 2016;90:1788-1801.
263. Wang B, Zhang Y, Jiang W, et al. GALNT3 inhibits NF-κB signaling during influenza a virus infection. Biochem Biophys Res Commun. 2018;503:2872-2877.
264. Shahzad-ul-Hussan S, Sastry M, Lemmin T, et al. Insights from NMR spectroscopy into the conformational properties of Man-9 and its recognition by two HIV binding proteins. Chembiochem. 2017;18:764-771.
265. Foulquier F, Amyere M, Jaeken J, et al. TMEM165 deficiency causes a congenital disorder of glycosylation. Am J Hum Genet. 2012;91:15-26.
266. Zeevaert R et al. Bone dysplasia as a key feature in three patients with a novel congenital disorder of glycosylation (CDG) type II due to a deep Intronic splice mutation in TMEM165. JIMD Rep. 2013;8:145-152.
267. Liu M-J, Bao S, Gálvez-Peralta M, et al. ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB. Cell Rep. 2013;3:386-400.
268. Truin G, Guillard M, Lefeber DJ, et al. Pericardial and abdominal fluid accumulation in congenital disorder of glycosylation type Ia. Mol Genet Metab. 2008;94:481-484.
269. Ng BG, Rosenfeld JA, Emrick L, et al. Pathogenic variants in Fucokinase cause a congenital disorder of glycosylation. Am J Hum Genet. 2018;103:1030-1037.
270. Zhang P, Haryadi R, Chan KF, et al. Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant. Glycobiology. 2012;22:897-911.
271. Tissue expression of FUT8—The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000033170-FUT8/tissue. Accessed March 14, 2019.
272. Tissue expression of SLC35C1—The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000181830-SLC35C1/tissue. Accessed March, 2019.
273. Mkhikian H, Mortales CL, Zhou RW, et al. Golgi self-correction generates bioequivalent glycans to preserve cellular homeostasis. Elife. 2016;5:e14814.